Inozyme Pharma (INZY)
(Delayed Data from NSDQ)
$4.40 USD
-0.05 (-1.12%)
Updated Apr 23, 2024 03:59 PM ET
After-Market: $4.41 +0.01 (0.23%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Detailed Estimates
EPS Estimates
Exp Earnings Date | 5/14/24 |
---|---|
Current Quarter | -0.35 |
EPS Last Quarter | -0.35 |
Last EPS Surprise | -12.90% |
ABR | 1.17 |
Earnings ESP
|
0.00% |
---|---|
Current Year | -1.46 |
Next Year | -1.58 |
EPS (TTM) | -1.39 |
P/E (F1) | NA |
Sales Estimates
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | NA | NA | NA | NA |
# of Estimates | NA | NA | NA | NA |
High Estimate | NA | NA | NA | NA |
Low Estimate | NA | NA | NA | NA |
Year ago Sales | 0.00M | 0.00M | NA | NA |
Year over Year Growth Est. | NA | NA | NA | NA |
Earnings Estimates
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | -0.35 | -0.39 | -1.46 | -1.58 |
# of Estimates | 5 | 3 | 5 | 5 |
Most Recent Consensus | -0.35 | -0.36 | -1.53 | -1.69 |
High Estimate | -0.30 | -0.36 | -1.10 | -1.30 |
Low Estimate | -0.38 | -0.41 | -1.67 | -1.89 |
Year ago EPS | -0.40 | -0.35 | -1.37 | -1.46 |
Year over Year Growth Est. | 12.50% | -11.43% | -6.57% | -7.95% |
Agreement - Estimate Revisions
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Up Last 7 Days | 0 | 0 | 0 | 0 |
Up Last 30 Days | 0 | 0 | 1 | 1 |
Up Last 60 Days | 0 | 1 | 2 | 0 |
Down Last 7 Days | 0 | 0 | 0 | 0 |
Down Last 30 Days | 0 | 0 | 0 | 0 |
Down Last 60 Days | 1 | 1 | 2 | 4 |
Magnitude - Consensus Estimate Trend
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Current | -0.35 | -0.39 | -1.46 | -1.58 |
7 Days Ago | -0.35 | -0.39 | -1.46 | -1.58 |
30 Days Ago | -0.35 | -0.39 | -1.48 | -1.58 |
60 Days Ago | -0.35 | -0.39 | -1.35 | -1.49 |
90 Days Ago | -0.35 | -0.39 | -1.35 | -1.49 |
Upside - Most Accurate Estimate Versus Zacks Consensus
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Most Accurate Estimate | -0.35 | -0.39 | -1.38 | -1.42 |
Zacks Consensus Estimate | -0.35 | -0.39 | -1.46 | -1.58 |
Earnings ESP | 0.00% | 0.00% | 5.61% | 10.01% |
Surprise - Reported Earnings History
Quarter Ending (12/2023) |
Quarter Ending (9/2023) |
Quarter Ending (6/2023) |
Quarter Ending (3/2023) |
Average Surprise | |
---|---|---|---|---|---|
Reported | -0.35 | -0.29 | -0.35 | -0.40 | NA |
Estimate | -0.31 | -0.32 | -0.43 | -0.44 | NA |
Difference | -0.04 | 0.03 | 0.08 | 0.04 | 0.03 |
Surprise | -12.90% | 9.38% | 18.60% | 9.09% | 6.04% |
Quarterly Estimates By Analyst
Zacks Premium Subscription Required Learn more
Annual Estimates By Analyst
Zacks Premium Subscription Required Learn more